B+
Bull case
20%
Probability
Target price
$5.00
Analysis reference price unavailable
Analysis 2026-07-21 · RankAlpha Sentiment Codex
CLLS
CellectisDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$2.80
Analysis reference price unavailable
Analysis 2026-07-21 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.40
Analysis reference price unavailable
Analysis 2026-07-21 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-07-21
Recent news sentiment (30D)
+0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+52.4
Score
AI commentary
Primary company news flow improved in June after the RMAT designation and EHA data release. The packet also contains a secondary report of a more than 24% after-hours rally, but no analyst revisions or social coverage are available; confidence therefore remains low and event-monitoring oriented.
RankAlpha Sentiment Codex - 2026-07-21
Open full AI memoEvidence flagged
small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-07-31catalystRMAT designation and EHA clinical update support near-term attentionHigh impact
Cellectis reported FDA RMAT designation for lasme-cel in relapsed/refractory B-ALL, followed by final Phase 1 BALLI-01 and preliminary eti-cel data at EHA 2026. The evidence improves regulatory and clinical visibility but remains early-stage. [#IR-2026-06-09] [#IR-2026-06-11]
2026-10-31eventBALLI-01 pivotal Phase 2 interim analysisHigh impact
The first interim analysis of pivotal Phase 2 BALLI-01 is expected in Q4 2026. A supportive result could materially improve program credibility, while weak efficacy or safety could reset expectations. [#IR-2026-05-11]
2026-12-31catalystNATHALI-01 full Phase 1 datasetHigh impact
Cellectis expects the full Phase 1 NATHALI-01 dataset for eti-cel in relapsed/refractory B-cell non-Hodgkin lymphoma in Q4 2026. Positive data could broaden platform value, but this remains secondary to BALLI-01 and early clinical evidence. [#IR-2026-05-11] [#IR-2026-06-11]
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology